casemark/analyzing-investor-advisory-committees

Analyzing Investor Advisory Committees

Structures IAC/LPAC design with composition, authority scope, conflict review protocols, and valuation oversight.

When To Use

• Designing a new IAC or LPAC for a fund vehicle (private equity, venture, credit, real estate, infrastructure)
• Reviewing or benchmarking an existing committee's scope of authority against market terms
• Structuring conflict-of-interest review and consent protocols for GP-LP transactions
• Defining valuation oversight responsibilities and committee involvement in fair-value determinations
• Evaluating whether committee composition satisfies side-letter commitments or regulatory expectations

Inputs To Gather

• LPA / Partnership Agreement — current draft or executed version with IAC/LPAC provisions
• Side letters — any commitments granting specific LPs committee seats, observer rights, or enhanced consent rights
• Fund term sheet or PPM — stated committee authority, composition targets, and voting thresholds
• GP conflict-of-interest policy — existing framework for identifying, disclosing, and resolving conflicts
• Valuation policy — fund-level valuation methodology and any committee role in override or escalation
• Investor base profile — LP types (pension, sovereign wealth, endowment, fund-of-funds, family office), commitment sizes, and governance expectations
• Regulatory considerations — jurisdiction-specific rules affecting committee authority (e.g., ERISA plan asset rules, AIFMD requirements) [VERIFY]

Workflow

1. Map existing provisions — Extract all IAC/LPAC references from the LPA, side letters, and PPM. Catalog each grant of authority, consent right, and information right.
2. Analyze committee composition
   • Identify seat allocation criteria: commitment size thresholds, LP-type diversity requirements, independent member slots
   • Flag whether any single LP or LP bloc holds a controlling number of seats
   • Confirm whether side-letter most-favored-nation (MFN) clauses could expand committee membership beyond planned size
3. Define authority scope — Classify each committee power:
   • Consent rights — transactions requiring affirmative LPAC approval (affiliated co-investments, GP-led secondaries, cross-fund investments, principal transactions, allocation of broken-deal expenses)
   • Advisory/consultation rights — matters where GP must seek input but retains final decision authority (extension of fund term, key-person replacement, changes to investment strategy)
   • Waiver authority — conflicts the committee may waive on behalf of all LPs vs. conflicts requiring full LP consent [VERIFY jurisdiction-specific fiduciary implications]
4. Evaluate conflict review protocols
   • Confirm the disclosure standard: does the GP provide full disclosure of material facts or a summary notice?
   • Check response mechanics: deemed-consent timelines, quorum requirements, voting thresholds (majority vs. supermajority), recusal rules for conflicted members
   • Assess whether the LPA specifies consequences of committee failure to respond (deemed approval vs. deemed denial)
5. Assess valuation oversight role
   • Determine committee involvement: review-only, consent to methodology changes, approval of write-downs/write-ups above a materiality threshold
   • Evaluate interaction with third-party valuation agents and audit firm reliance on committee determinations
   • Flag any provisions where committee valuation authority could create LP liability or co-fiduciary risk [VERIFY under applicable partnership law]
6. Benchmark against market standards — Compare committee terms to current market norms for the fund's strategy and vintage. Note deviations that may attract LP pushback or give the GP unusual discretion.
7. Identify structural risks — Flag gaps such as absence of indemnification for committee members, no confidentiality obligations, lack of expense-reimbursement provisions, or missing procedures for replacing departing members.

Output

Produce a structured analysis report containing:

• Committee composition summary — seat count, allocation methodology, current or proposed members, and term/rotation mechanics
• Authority matrix — table mapping each conflict or decision category to the applicable committee power (consent, advisory, waiver, none) with LPA section references
• Conflict review process map — step-by-step flow from GP disclosure through committee response, including timelines and default outcomes
• Valuation oversight summary — committee role relative to GP, third-party valuers, and auditors
• Market-comparison notes — key deviations from prevailing market terms with risk commentary
• Recommendations — specific drafting or structural changes to address identified gaps or risks

Quality Checks

• Every committee power cited traces to a specific LPA section or side-letter provision
• Consent vs. advisory vs. waiver authority is clearly distinguished — no conflation of categories
• Deemed-consent mechanics and quorum rules are fully specified (not left ambiguous)
• Side-letter MFN effects on composition and authority are accounted for
• [VERIFY] markers applied to all jurisdiction-dependent points: fiduciary standards for committee waiver authority, ERISA plan-asset implications, tax-exempt investor constraints, and non-U.S. regulatory requirements
• Valuation oversight analysis addresses whether committee involvement creates unintended liability exposure for sitting members
• Recommendations are concrete and drafting-ready, not abstract policy suggestions